TIDMAPH
RNS Number : 6061C
Alliance Pharma PLC
02 October 2018
For immediate release 2 October 2018
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Xonvea(R) launch in the UK
Alliance Pharma plc (AIM: APH), the international specialty
pharmaceutical company, announces that it has today launched
Xonvea, its prescription product for the treatment of nausea and
vomiting of pregnancy (NVP), in the UK. Xonvea is a new licensed
medicine available in the UK for women with NVP where conservative
management has failed.
NVP is the most common medical condition in pregnancy affecting
approximately 751,923 women in the UK each year, according to the
Office of National Statistics and the Royal College of
Obstetricians and Gynaecologists(1,2) . Research shows that up to
40% of pregnant women report symptoms of NVP sufficiently severe to
interfere with daily life(3-6) and that symptoms can be compared in
severity to the nausea associated with chemotherapy(7) . Reported
feelings of anxiety and depression from NVP have been shown to
approach levels seen in women with post-natal depression(3,8) .
The Royal College of Obstetricians and Gynaecologists states
that severe NVP is one of the most common reasons for pregnant
women to be admitted to hospital(2) . In 2016-2017, there were
33,071 hospital admissions for NVP in England, resulting in 36,171
bed days according to the NHS(9) .
Professor Catherine Nelson-Piercy, consultant obstetric
physician, commented:
"I am delighted that at last the UK has a licensed medication
for the treatment of nausea and vomiting of pregnancy where
conservative treatment has failed. This delayed release formulation
of doxylamine and pyridoxine has been used in millions of pregnant
women worldwide. Primary and secondary care doctors caring for
pregnant women in the UK are now able to prescribe Xonvea,
affording women in the UK a licensed option when it comes to
managing this often debilitating condition. In women who do not
respond completely to Xonvea, doctors can prescribe other
anti-sickness drugs recommended by National Clinical
Guidelines."
Peter Butterfield, Alliance Pharma's Chief Executive Officer,
said:
"The launch of Xonvea is a significant milestone for Alliance
and I'm delighted that we have today made the product available in
the UK. There is no other licensed treatment for nausea and
vomiting of pregnancy in the UK so this is excellent news for
patients and clinicians as it fulfils a significant unmet medical
need."
Alliance in-licensed Xonvea from Duchesnay Inc. of Canada for
the UK in 2015. Xonvea's combination of doxylamine and pyridoxine
is recommended as a first-line pharmacotherapy in the USA and
Canada and has been prescribed to over 33 million women in more
than 40 years(3,10-15) .
Éric Gervais, Duchesnay's Executive Vice-President, added:
"With the launch of Xonvea, Duchesnay is proud to provide women
in the UK with something they have been without for years: a
licensed treatment to help relieve nausea and vomiting of
pregnancy."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
www.alliancepharma.co.uk
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma
Mostyn-Owen
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade /
Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
David Herring
Notes to editors:
Alliance Pharma plc is an international specialty pharmaceutical
company.
Headquartered in Chippenham, UK, Alliance commenced trading in
1998 and has been listed on AIM since 2003. Alliance has a strong
track record of acquiring established niche products and it
currently owns or licenses the rights to approximately 90
pharmaceutical and consumer healthcare products. It has sales in
more than 100 countries either directly via its affiliates or
through its selected network of distributor partners. Alliance
joined the AIM market of the London Stock Exchange in December 2003
and trades under the symbol APH.
Duchesnay Inc. is a North American specialty pharmaceutical
company.
Headquartered in Blainville, Canada, Duchesnay is a specialty
pharmaceutical company with a long-standing commitment to women's
health. The company focuses on filling the void in terms of
scientific research and education and on developing pharmacological
solutions that have established safety and efficacy profiles for
use during pregnancy and breastfeeding. With offices in Canada and
the United States, Duchesnay also commercializes a broad portfolio
of products to offer proven therapeutic options that meet the
health and quality of life needs of women and their family members
at various stages of their lives.
References:
1. Office for National Statistics.: 2016. Statistical bulletin,
27 March 2018. Available at: https://www.
ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages.
Accessed May 2018.
2. Royal College of Obstetricians and Gynaecologists. The
management of nausea and vomiting of pregnancy and hyperemesis
gravidarum (Green-top Guideline No. 69). 22 June 2016. Royal
College of Obstetricians and Gynaecologists: London.
https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg69/.
3. Association of Professors of Gynecology and Obstetrics.
Nausea and Vomiting of Pregnancy. Continuing series on Women's
Health Education. 2011; Jespersen & Associates, LLC, Boston,
Massachusetts.
4. Mazzotta P. Psychosocial Morbidity Among Women with Nausea
and Vomiting of Pregnancy: Prevalence: Prevalence and Association
with Anti-Emetic Therapy. J. Psychosom Obstet Gynecol 2000;21:
129-136
5. O'Brien B et al. Nausea and vomiting during pregnancy:
effects on the quality of women's lives. Birth 1992;
19:138-143.
6. Vellacott ID et al. Nausea and vomiting in early pregnancy.
Int J Gynecol Obstet. 1988;27:57-62.
7. Lacroix R, Eason E, Melzack R. Nausea and vomiting during
pregnancy: a prospective study of its frequency, intensity, and
patterns of change. Am J Obstet Gynecol 2000; 182(4): 931-937.
8. Lacasse A, Rey E, Ferreira E, Morin C, Be'rard A. Nausea and
vomiting of pregnancy: what about quality of life? BJOG
2008;115:1484-1493
9. NHS Digital. HES data 2016/17. Available at: https://digital.nhs.uk/data-and-information/ publications/statistical/hospital-admitted-patient-care-activity/2016-17. Accessed July 2018.
10. The Society of Obstetricians and Gynaecologists of Canada. J
Obstet Gynaecol Can. 2016;38(12):1127-1137.
11. American College of Obstetricians and Gynecologists. ACOG
Practice Bulletin No. 189, January 2018. Nausea and vomiting of
pregnancy. Obstet. Gynecol. 2018;131:e15-e30.
12. Institute of Obstetricians & Gynaecologists Clinical
Practice Guidelines, Royal College of Physicians of Ireland.
Hyperemesis and nausea/vomiting in pregnancy. Guideline 12; v1 (Nov
2015).
13. Spanish Society of Gynecology & Obstetrics (SEGO)
Consensus Document Hyperemesis Gravidarum; 2008:61-100.
14. Ornstein, M., Einarson, A., Koren, G. Bendectin/Diclectin
for morning sickness: A Canadian follow-up of an American tragedy.
Reproductive Toxicology. 1995; 9(1): 1-6.
15. Madjunkova S et al. The delayed-release combination of
doxylamine and pyridoxine (Diclegis(R)/Diclectin(R)) for the
treatment of nausea and vomiting of pregnancy. Pediatr Drugs
2014;16:199-211.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PRLFSSFMFFASEIS
(END) Dow Jones Newswires
October 02, 2018 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024